Andrew Davis is Senior Vice President of Corporate Development, Strategy and Valuation at Ironwood. Before joining the company in May 2021, Mr. Davis served as the Chief Business Development and M&A Officer at iNova Pharmaceuticals for nearly four years, leading all company transactions and acting as a member of the executive management team. Prior to iNova, Mr. Davis was Head of Oncology Business Development for Merck. Before his time at Merck, Mr. Davis was at Bausch Health (formerly Valeant Pharmaceuticals) where he held roles of increasing responsibility within the Business Development function, ultimately serving as Senior Vice President of Business Development and leading all transactions for the company from 2014 to 2016, including the acquisitions of Salix Pharmaceuticals and Bausch and Lomb. Mr. Davis began his career as an analyst at McKinsey & Co., where his work focused on the healthcare space. Mr. Davis has a B.A. in economics from Boston University and is currently on the board of directors of Biomarck Pharmaceuticals, Ltd. and UTILITY therapeutics.